Molecular and biological aspects of the bovine immunodeficiency virus

Current HIV Research

Volumn 8, Issue 1, 2010, Pages 2-13

  Corredor, Andrea G ^a   St Louis, Marie Claude ^a   Archambault, Denis ^a  

^a UNIVERSITÉ DU QUÉBEC À MONTRÉAL   (Canada)

Author keywords

Bovine immunodeficiency virus; Genetic diversity; Structural proteins; Tat and Rev proteins

Indexed keywords

REV PROTEIN; STRUCTURAL PROTEIN; TRANSACTIVATOR PROTEIN;

BOVINE IMMUNODEFICIENCY LIKE VIRUS; CATTLE DISEASE; GENE EXPRESSION REGULATION; GENETIC VARIABILITY; HUMAN IMMUNODEFICIENCY VIRUS 1; LENTIVIRINAE; NONHUMAN; REVIEW; SEQUENCE ANALYSIS; SEROPREVALENCE; VIRUS EXPRESSION; VIRUS GENE; VIRUS GENOME; WASTING SYNDROME;

ANIMALS; BASE SEQUENCE; CATTLE; GENE PRODUCTS, TAT; IMMUNODEFICIENCY VIRUS, BOVINE; LENTIVIRUS INFECTIONS; MOLECULAR SEQUENCE DATA; RETROVIRIDAE PROTEINS; TERMINAL REPEAT SEQUENCES;

EID: 77949758196     PISSN: 1570162X     EISSN: None     Source Type: Journal    
DOI: 10.2174/157016210790416343     Document Type: Review

References (154)

1. Goff SP. Retroviridae: TheRetroviruses and Their Replication. In: Knipe DMH, Peter M, Eds. Fields Virology: Lippincott Williams and Wilkins 2007; pp. 2001-69.
2. Gifford RJ, Katzourakis A, Tristem M, Pybus OG, Winters M, Shafer RW. A transitional endogenous lentivirus from the genome of a basal primate and implications for lentivirus evolution. Proc Natl Acad Sci USA 2008; 105: 20362-67.
3. th ed. Lippincott Williams and Wilkins. 2007; pp. 2216-43.
4. Borrow P, Lewicki H, Wei X, et al. Antiviral pressure exerted by HIV-1-specific cytotoxic T lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus. Nat Med 1997; 3: 205-11.
5. Burns DP, Desrosiers RC. Envelope sequence variation, neutralizing antibodies, and primate lentivirus persistence. Curr Top Microbiol Immunol 1994; 188: 185-219.
6. Narayan O, Clements JE, Griffin DE, Wolinsky JS. Neutralizing antibody spectrum determines the antigenic profiles of emerging mutants of visna virus. Infect Immun 1981; 32: 1045-50.
7. Payne SL, Fang FD, Liu CP, et al. Antigenic variation and lentivirus persistence: variations in envelope gene sequences during EIAV infection resemble changes reported for sequential isolates of HIV. Virology 1987; 161: 321-31.
8. Carter CA, Ehrlich LS. Cell biology of HIV-1 infection of macrophages. Annu Rev Microbiol 2008; 62: 425-43.
9. Terzieva V. Regulatory T cells and HIV-1 infection. Viral Immunol 2008; 21: 285-91.
10. VandeWoude S, Apetrei C. Going wild: lessons from naturally occurring T-lymphotropic lentiviruses. Clin Microbiol Rev 2006; 19: 728-62.
11. Moanna A, Dunham R, Paiardini M, Silvestri G. CD4+ T-cell depletion in HIV infection: killed by friendly fire? Curr HIV/AIDS Rep 2005; 2: 16-23.
12. St-Louis MC, Cojocariu M, Archambault D. The molecular biology of bovine immunodeficiency virus: a comparison with other lentiviruses. Anim Health Res Rev 2004; 5: 125-43.
13. Malmquist WA, Van der Maaten MJ, Boothe AD. Isolation, immunodiffusion, immunofluorescence, and electron microscopy of a syncytial virus of lymphosarcomatous and apparently normal cattle. Cancer Res 1969; 29: 188-200.
14. Van der Maaten MJ, Malmquist WA, Cheville NF. Susceptibility of calves to bovine syncytial virus given by different inoculation routes. Am J Vet Res 1972; 33: 1157-60.
15. Barre-Sinoussi F, Chermann JC, Rey F, et al. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science 1983; 220: 868-71.
16. Gonda MA, Braun MJ, Carter SG, et al. Characterization and molecular cloning of a bovine lentivirus related to human immunodeficiency virus. Nature 1987; 330: 388-91.
17. Chadwick BJ, Coelen RJ, Sammels LM, Kertayadnya G, Wilcox GE. Genomic sequence analysis identifies Jembrana disease virus as a new bovine lentivirus. J Gen Virol 1995; 76(Pt 1): 189-92.
18. Chadwick BJ, Coelen RJ, Wilcox GE, Sammels LM, Kertayadnya G. Nucleotide sequence analysis of Jembrana disease virus: a bovine lentivirus associated with an acute disease syndrome. J Gen Virol 1995; 76 (Pt 7): 1637-50.
19. Wareing S, Hartaningsih N, Wilcox GE, Penhale WJ. Evidence for immunosuppression associated with Jembrana disease virus infection of cattle. Vet Microbiol 1999; 68: 179-85.
20. Wilcox GE, Chadwick BJ, Kertayadnya G. Recent advances in the understanding of Jembrana disease. Vet Microbiol 1995; 46: 249-55.
21. Bhatia S, Sood R, Bhatia AK, Pattnaik B, Pradhan HK. Development of a capsid based competitive inhibition enzymelinked immunosorbent assay for detection of bovine immunodeficiency virus antibodies in cattle and buffalo serum. J Virol Methods 2008; 148: 218-25.
22. Gonzalez ET, Licursi M, Vila Roza V, et al. Evidence of bovine immunodeficiency virus (BIV) infection: serological survey in Argentina. Res Vet Sci 2008; 85: 353-8.
23. Carpenter S, Miller LD, Alexandersen S, et al. Characterization of early pathogenic effects after experimental infection of calves with bovine immunodeficiency-like virus. J Virol 1992; 66: 1074-83.
24. Onuma M, Koomoto E, Furuyama H, et al. Infection and dysfunction of monocytes induced by experimental inoculation of calves with bovine immunodeficiency-like virus. J Acquir Immune Defic Syndr 1992; 5: 1009-15.
25. Zhang S, Wood C, Xue W, Krukenberg SM, Chen Q, Minocha HC. Immune suppression in calves with bovine immunodeficiency virus. Clin Diagn Lab Immunol 1997; 4: 232-5.
26. Jacobs RM, Pollari FL, McNab WB, Jefferson B. A serological survey of bovine syncytial virus in Ontario: associations with bovine leukemia and immunodeficiency-like viruses, production records, and management practices. Can J Vet Res 1995; 59: 271-8.
27. McNab WB, Jacobs RM, Smith HE. A serological survey for bovine immunodeficiency-like virus in Ontario dairy cattle and associations between test results, production records and management practices. Can J Vet Res 1994; 58: 36-41.
28. Hirai N, Kabeya H, Ohashi K, Sugimoto C, Onuma M. Immunomodulative effects of bovine immunodeficiency-like virus (BIV)-infection and mixed infection of BIV and bovine leukemia virus on sheep. Jpn J Vet Res 1996; 44: 153-63.
29. Martin SJ, O'Neill TP, Bilello JA, Eiseman JL. Lymphocyte transformation abnormalities in bovine immunodeficiency-like virus infected calves. Immunol Lett 1991; 27: 81-4.
30. Kalvatchev Z, Walder R, Barrios M, Garzaro D. Acquired immune dysfunction in rabbits experimentally infected with an infectious molecular clone of the bovine immunodeficiency virus (BIV127). Viral Immunol 1995; 8: 159-64.
31. Kalvatchev Z, Walder R, Perez F, Garzaro D, Barrios M. Infection of rabbits with R29 strain of bovine immunodeficiency virus: virulence, immunosuppression, and progressive mesenteric lymphadenopathy. Viral Immunol 1998; 11: 159-66.
32. Meas S, Usui T, Ohashi K, Sugimoto C, Onuma M. Vertical transmission of bovine leukemia virus and bovine immunodeficiency virus in dairy cattle herds. Vet Microbiol 2002; 84: 275-82.
33. Moody CA, Pharr GT, Murphey J, et al. Confirmation of vertical transmission of bovine immunodeficiency virus in naturally infected dairy cattle using the polymerase chain reaction. J Vet Diagn Invest 2002; 14: 113-9.
34. Moore EC, Keil D, Coats KS. Thermal inactivation of bovine immunodeficiency virus. Appl Environ Microbiol 1996; 62: 4280-3.
35. Munro R, Lysons R, Venables C, Horigan M, Jeffrey M, Dawson M. Lymphadenopathy and non-suppurative meningo-encephalitis in calves experimentally infected with bovine immunodeficiency-like virus (FL112). J Comp Pathol 1998; 119: 121-34.
36. Nash JW, Hanson LA, St Cyr Coats K. Detection of bovine immunodeficiency virus in blood and milk-derived leukocytes by use of polymerase chain reaction. Am J Vet Res 1995; 56: 445-9.
37. Snider TG, Hoyt PG, Jenny BF, et al. Natural and experimental bovine immunodeficiency virus infection in cattle. Vet Clin North Am Food Anim Pract 1997; 13: 151-76.
38. Venables C, Lysons R, Horigan M, Stagg D, Dawson M. Bovine immunodeficiency-like virus: inactivation in milk by pasteurisation. Vet Rec 1997; 140: 275-7.
39. Baron T, Mallet F, Polack B, Betemps D, Belli P. The bovine immunodeficiency-like virus (BIV) is transcriptionally active in experimentally infected calves. Arch Virol 1995; 140: 1461-7.
40. Gonda MA, Oberste MS, Garvey KJ, et al. Development of the bovine immunodeficiency-like virus as a model of lentivirus disease. Dev Biol Stand 1990; 72: 97-110.
41. Gradil CM, Watson RE, Renshaw RW, Gilbert RO, Dubovi EJ. Detection of bovine immunodeficiency virus DNA in the blood and semen of experimentally infected bulls. Vet Microbiol 1999; 70: 21-31.
42. Pifat DY, Ennis WH, Ward JM, Oberste MS, Gonda MA. Persistent infection of rabbits with bovine immunodeficiency-like virus. J Virol 1992; 66: 4518-24.
43. Zhang S, Troyer DL, Kapil S, et al. Detection of proviral DNA of bovine immunodeficiency virus in bovine tissues by polymerase chain reaction (PCR) and PCR in situ hybridization. Virology 1997; 236: 249-57.
44. Bouillant AM, Ruckerbauer GM, Nielsen KH. Replication of the bovine immunodeficiency-like virus in diploid and aneuploid cells: permanent, latent and virus-productive infections in vitro. Res Virol 1989; 140: 511-29.
45. Fong SE, Greenwood JD, Williamson JC, et al. Bovine immunodeficiency virus tat gene: cloning of two distinct cDNAs and identification, characterization, and immunolocalization of the tat gene products. Virology 1997; 233: 339-57.
46. Kempster S, Collins ME, Brownlie J. Tat protein expression in MDBK cells does not confer susceptibility to bovine immunodeficiency virus. Arch Virol 2002; 147: 643-9.
47. Gonda MA, Luther DG, Fong SE, Tobin GJ. Bovine immunodeficiency virus: molecular biology and virus-host interactions. Virus Res 1994; 32: 155-81.
48. Garvey KJ, Oberste MS, Elser JE, Braun MJ, Gonda MA. Nucleotide sequence and genome organization of biologically active proviruses of the bovine immunodeficiency-like virus. Virology 1990; 175: 391-409.
49. Oberste MS, Williamson JC, Greenwood JD, Nagashima K, Copeland TD, Gonda MA. Characterization of bovine immunodeficiency virus rev cDNAs and identification and subcellular localization of the Rev protein. J Virol 1993; 67: 6395-405.
50. Fong SE, Pallansch LA, Mikovits JA, Lackman-Smith CS, Ruscetti FW, Gonda MA. cis-acting regulatory elements in the bovine immunodeficiency virus long terminal repeat. Virology 1995; 209: 604-14.
51. Chen L, Frankel AD. An RNA-binding peptide from bovine immunodeficiency virus Tat protein recognizes an unusual RNA structure. Biochemistry 1994; 33: 2708-15.
52. Oberste MS, Greenwood JD, Gonda MA. Analysis of the transcription pattern and mapping of the putative rev and env splice junctions of bovine immunodeficiency-like virus. J Virol 1991; 65: 3932-7.
53. Bukrinskaya AG. HIV-1 assembly and maturation. Arch Virol 2004; 149: 1067-82.
54. Forshey BM, von Schwedler U, Sundquist WI, Aiken C. Formation of a human immunodeficiency virus type 1 core of optimal stability is crucial for viral replication. J Virol 2002; 76: 5667-77.
55. Battles JK, Hu MY, Rasmussen L, Tobin GJ, Gonda MA. Immunological characterization of the gag gene products of bovine immunodeficiency virus. J Virol 1992; 66: 6868-77.
56. Rasmussen L, Battles JK, Ennis WH, Nagashima K, Gonda MA. Characterization of virus-like particles produced by a recombinant baculovirus containing the gag gene of the bovine immunodeficiency-like virus. Virology 1990; 178: 435-51.
57. nd, Fabris D, et al. Amino acid sequence analysis of the proteolytic cleavage products of the bovine immunodeficiency virus Gag precursor polypeptide. J Virol 1994; 68: 7620-7.
58. Guo X, Hu J, Whitney JB, Russell RS, Liang C. Important role for the CA-NC spacer region in the assembly of bovine immunodeficiency virus Gag protein. J Virol 2004; 78: 551-60.
59. Avidan O, Bochner R, Hizi A. The catalytic properties of the recombinant reverse transcriptase of bovine immunodeficiency virus. Virology 2006; 351: 42-57.
60. Elder JH, Lerner DL, Hasselkus-Light CS, et al. Distinct subsets of retroviruses encode dUTPase. J Virol 1992; 66: 1791-4.
61. Threadgill DS, Steagall WK, Flaherty MT, et al. Characterization of equine infectious anemia virus dUTPase: growth properties of a dUTPase-deficient mutant. J Virol 1993; 67: 2592-600.
62. Payne SL, Elder JH. The role of retroviral dUTPases in replication and virulence. Curr Protein Pept Sci 2001; 2: 381-8.
63. Avidan O, Hizi A. Expression and characterization of the integrase of bovine immunodeficiency virus. Virology 2008; 371: 309-21.
64. Cherepanov P. LEDGF/p75 interacts with divergent lentiviral integrases and modulates their enzymatic activity in vitro. Nucleic Acids Res 2007; 35: 113-24.
65. Engelman A, Cherepanov P. The lentiviral integrase binding protein LEDGF/p75 and HIV-1 replication. PLoS Pathog 2008; 4: e1000046.
66. Rasmussen L, Greenwood JD, Gonda MA. Expression of bovine immunodeficiency-like virus envelope glycoproteins by a recombinant baculovirus in insect cells. Virology 1992; 186: 551-61.
67. Gaines H, von Sydow M, Sonnerborg A, et al. Antibody response in primary human immunodeficiency virus infection. Lancet 1987; 1: 1249-53.
68. Whetstone CA, VanDerMaaten MJ, Black JW. Humoral immune response to the bovine immunodeficiency-like virus in experimentally and naturally infected cattle. J Virol 1990; 64: 3557-61.
69. Abed Y, Archambault D. A viral transmembrane recombinant protein-based enzyme-linked immunosorbent assay for the detection of bovine immunodeficiency virus infection. J Virol Methods 2000; 85: 109-16.
70. Abed Y, St-Laurent G, Zhang H, Jacobs RM, Archambault D. Development of a Western blot assay for detection of bovine immunodeficiency-like virus using capsid and transmembrane envelope proteins expressed from recombinant baculovirus. Clin Diagn Lab Immunol 1999; 6: 168-72.
71. Isaacson JA, Roth JA, Wood C, Carpenter S. Loss of Gag-specific antibody reactivity in cattle experimentally infected with bovine immunodeficiency-like virus. Viral Immunol 1995; 8: 27-36.
72. Barboric M, Taube R, Nekrep N, Fujinaga K, Peterlin BM. Binding of Tat to TAR and recruitment of positive transcription elongation factor b occur independently in bovine immunodeficiency virus. J Virol 2000; 74: 6039-44.
73. Chen H, Wilcox G, Kertayadnya G, Wood C. Characterization of the Jembrana disease virus tat gene and the cis- and transregulatory elements in its long terminal repeats. J Virol 1999; 73: 658-66.
74. Gunnery S, Green SR, Mathews MB. Tat-responsive region RNA of human immunodeficiency virus type 1 stimulates protein synthesis in vivo and in vitro: relationship between structure and function. Proc Natl Acad Sci USA 1992; 89: 11557-61.
75. McCloskey TW, Ott M, Tribble E, et al. Dual role of HIV Tat in regulation of apoptosis in T cells. J Immunol 1997; 158: 1014-9.
76. Xuan C, Qiao W, Li J, et al. BTat, a trans-acting regulatory protein, contributes to bovine immunodeficiency virus-induced apoptosis. Cell Microbiol 2008; 10: 31-40.
77. Liu ZQ, Sheridan D, Wood C. Identification and characterization of the bovine immunodeficiency-like virus tat gene. J Virol 1992; 66: 5137-40.
78. Pallansch LA, Lackman-Smith CS, Gonda MA. Bovine immunodeficiency-like virus encodes factors which trans activate the long terminal repeat. J Virol 1992; 66: 2647-52.
79. St-Louis MC, Abed Y, Archambault D. The bovine immunodeficiency virus: cloning of a tat/rev cDNA encoding a novel Tat protein with enhanced transactivation activity. Arch Virol 2005; 150: 1529-47.
80. Carpenter S, Nadin-Davis SA, Wannemuehler Y, Roth JA. Identification of transactivation-response sequences in the long terminal repeat of bovine immunodeficiency-like virus. J Virol 1993; 67: 4399-403.
81. Ruben S, Perkins A, Purcell R, et al. Structural and functional characterization of human immunodeficiency virus tat protein. J Virol 1989; 63: 1-8.
82. Bieniasz PD, Grdina TA, Bogerd HP, Cullen BR. Recruitment of a protein complex containing Tat and cyclin T1 to TAR governs the species specificity of HIV-1 Tat. EMBO J 1998; 17: 7056-65.
83. Bogerd HP, Wiegand HL, Bieniasz PD, Cullen BR. Functional differences between human and bovine immunodeficiency virus Tat transcription factors. J Virol 2000; 74: 4666-71.
84. Efthymiadis A, Briggs LJ, Jans DA. The HIV-1 Tat nuclear localization sequence confers novel nuclear import properties. J Biol Chem 1998; 273: 1623-8.
85. Deng G, Qiao W, Su Y, Sha R, Geng Y, Chen Q. Internalization of Jembrana disease virus Tat: possible pathway and implication. Virus Res 2006; 121: 122-33.
86. Deng G, Su Y, Mu J, et al. Molecular basis of the internalization of bovine immunodeficiency virus Tat protein. Virus Genes 2008; 36: 85-94.
87. Tyagi M, Rusnati M, Presta M, Giacca M. Internalization of HIV-1 tat requires cell surface heparan sulfate proteoglycans. J Biol Chem 2001; 276: 3254-61.
88. Ensoli B, Buonaguro L, Barillari G, et al. Release, uptake, and effects of extracellular human immunodeficiency virus type 1 Tat protein on cell growth and viral transactivation. J Virol 1993; 67: 277-87.
89. Macian F, Rao A. Reciprocal modulatory interaction between human immunodeficiency virus type 1 Tat and transcription factor NFAT1. Mol Cell Biol 1999; 19: 3645-53.
90. Purvis SF, Georges DL, Williams TM, Lederman MM. Suppression of interleukin-2 and interleukin-2 receptor expression in Jurkat cells stably expressing the human immunodeficiency virus Tat protein. Cell Immunol 1992; 144: 32-42.
91. Buonaguro L, Barillari G, Chang HK, et al. Effects of the human immunodeficiency virus type 1 Tat protein on the expression of inflammatory cytokines. J Virol 1992; 66: 7159-67.
92. Marchio S, Alfano M, Primo L, et al. Cell surface-associated Tat modulates HIV-1 infection and spreading through a specific interaction with gp120 viral envelope protein. Blood 2005; 105: 2802-11.
93. Mischiati C, Pironi F, Milani D, et al. Extracellular HIV-1 Tat protein differentially activates the JNK and ERK/MAPK pathways in CD4 T cells. AIDS 1999; 13: 1637-45.
94. Garcia-Martinez LF, Mavankal G, Neveu JM, Lane WS, Ivanov D, Gaynor RB. Purification of a Tat-associated kinase reveals a TFIIH complex that modulates HIV-1 transcription. EMBO J 1997; 16: 2836-50.
95. Garber ME, Mayall TP, Suess EM, Meisenhelder J, Thompson NE, Jones KA. CDK9 autophosphorylation regulates high-affinity binding of the human immunodeficiency virus type 1 tat-P-TEFb complex to TAR RNA. Mol Cell Biol 2000; 20: 6958-69.
96. Okamoto H, Sheline CT, Corden JL, Jones KA, Peterlin BM. Trans-activation by human immunodeficiency virus Tat protein requires the C-terminal domain of RNA polymerase II. Proc Natl Acad Sci USA 1996; 93: 11575-9.
97. Ping YH, Rana TM. Tat-associated kinase (P-TEFb): a component of transcription preinitiation and elongation complexes. J Biol Chem 1999; 274: 7399-404.
98. Feng S, Holland EC. HIV-1 tat trans-activation requires the loop sequence within tar. Nature 1988; 334: 165-7.
99. Mancebo HS, Lee G, Flygare J, et al. P-TEFb kinase is required for HIV Tat transcriptional activation in vivo and in vitro. Genes Dev 1997; 11: 2633-44.
100. Zhang J, Tamilarasu N, Hwang S, et al. HIV-1 TAR RNA enhances the interaction between Tat and cyclin T1. J Biol Chem 2000; 275: 34314-9.
101. Fujinaga K, Cujec TP, Peng J, et al. The ability of positive transcription elongation factor B to transactivate human immunodeficiency virus transcription depends on a functional kinase domain, cyclin T1, and Tat. J Virol 1998; 72: 7154-9.
102. Herrmann CH, Rice AP. Lentivirus Tat proteins specifically associate with a cellular protein kinase, TAK, that hyperphosphorylates the carboxyl-terminal domain of the large subunit of RNA polymerase II: candidate for a Tat cofactor. J Virol 1995; 69: 1612-20.
103. Colvin RA, Garcia-Blanco MA. Unusual structure of the human immunodeficiency virus type 1 trans-activation response element. J Virol 1992; 66: 930-5.
104. Lustig B, Bahar I, Jernigan RL. RNA bulge entropies in the unbound state correlate with peptide binding strengths for HIV-1 and BIV TAR RNA because of improved conformational access. Nucleic Acids Res 1998; 26: 5212-7.
105. Lim AC, Barton JK. Targeting the Tat-binding site of bovine immunodeficiency virus TAR RNA with a shape-selective rhodium complex. Bioorg Med Chem 1997; 5: 1131-6.
106. Puglisi JD, Chen L, Blanchard S, Frankel AD. Solution structure of a bovine immunodeficiency virus Tat-TAR peptide-RNA complex. Science 1995; 270: 1200-3.
107. Calabro V, Daugherty MD, Frankel AD. A single intermolecular contact mediates intramolecular stabilization of both RNA and protein. Proc Natl Acad Sci USA 2005; 102: 6849-54.
108. Smith CA, Calabro V, Frankel AD. An RNA-binding chameleon. Mol Cell 2000; 6: 1067-76.
109. Kwak YT, Ivanov D, Guo J, Nee E, Gaynor RB. Role of the human and murine cyclin T proteins in regulating HIV-1 tat-activation. J Mol Biol 1999; 288: 57-69.
110. Ye X, Kumar RA, Patel DJ. Molecular recognition in the bovine immunodeficiency virus Tat peptide-TAR RNA complex. Chem Biol 1995; 2: 827-40.
111. Das C, Edgcomb SP, Peteranderl R, Chen L, Frankel AD. Evidence for conformational flexibility in the Tat-TAR recognition motif of cyclin T1. Virology 2004; 318: 306-17.
112. D'Orso I, Frankel AD. Tat acetylation modulates assembly of a viral-host RNA-protein transcription complex. Proc Natl Acad Sci USA 2009; 106: 3101-6.
113. Kiernan RE, Vanhulle C, Schiltz L, et al. HIV-1 tat transcriptional activity is regulated by acetylation. EMBO J 1999; 18: 6106-18.
114. Cullen BR. Nuclear mRNA export: insights from virology. Trends Biochem Sci 2003; 28: 419-24.
115. Pollard VW, Malim MH. The HIV-1 Rev protein. Annu Rev Microbiol 1998; 52: 491-532.
116. Narayan M, Younis I, D'Agostino DM, Green PL. Functional domain structure of human T-cell leukemia virus type 2 rex. J Virol 2003; 77: 12829-40.
117. Arnold M, Nath A, Hauber J, Kehlenbach RH. Multiple importins function as nuclear transport receptors for the Rev protein of human immunodeficiency virus type 1. J Biol Chem 2006; 281: 20883-90.
118. Lee JH, Murphy SC, Belshan M, et al. Characterization of functional domains of equine infectious anemia virus Rev suggests a bipartite RNA-binding domain. J Virol 2006; 80: 3844-52.
119. Younis I, Green PL. The human T-cell leukemia virus Rex protein. Front Biosci 2005; 10: 431-45.
120. Bohnlein E, Berger J, Hauber J. Functional mapping of the human immunodeficiency virus type 1 Rev RNA binding domain: new insights into the domain structure of Rev and Rex. J Virol 1991; 65: 7051-55.
121. Edgcomb SP, Aschrafi A, Kompfner E, Williamson JR, Gerace L, Hennig M. Protein structure and oligomerization are important for the formation of export-competent HIV-1 Rev-RRE complexes. Protein Sci 2008; 17: 420-30.
122. Zapp ML, Hope TJ, Parslow TG, Green MR. Oligomerization and RNA binding domains of the type 1 human immunodeficiency virus Rev protein: a dual function for an arginine-rich binding motif. Proc Natl Acad Sci USA 1991; 88: 7734-8.
123. Dong X, Biswas A, Suel KE, et al. Structural basis for leucine-rich nuclear export signal recognition by CRM1. Nature 2009; 458: 1136-41.
124. Tiley LS, Cullen BR. Structural and functional analysis of the visna virus Rev-response element. J Virol 1992; 66: 3609-15.
125. Boyer PL, Ferris AL, Hughes SH. Mutational analysis of the fingers domain of human immunodeficiency virus type 1 reverse transcriptase. J Virol 1992; 66: 7533-7.
126. Burke DS. Recombination in HIV: an important viral evolutionary strategy. Emerg Infect Dis 1997; 3: 253-9.
127. Mansky LM. Retrovirus mutation rates and their role in genetic variation. J Gen Virol 1998; 79(Pt 6): 1337-45.
128. Truyen U, Parrish CR, Harder TC, Kaaden OR. There is nothing permanent except change. The emergence of new virus diseases. Vet Microbiol 1995; 43: 103-22.
129. Chirmule N, Pahwa S. Envelope glycoproteins of human immunodeficiency virus type 1: profound influences on immune functions. Microbiol Rev 1996; 60: 386-406.
130. Cooper CR, Hanson LA, Diehl WJ, Pharr GT, Coats KS. Natural selection of the Pol gene of bovine immunodeficiency virus. Virology 1999; 255: 294-301.
131. Meas S, Ohashi K, Sugimoto C, Onuma M. Phylogenetic relationships of bovine immunodeficiency virus in cattle and buffaloes based on surface envelope gene sequences. Brief report. Arch Virol 2001; 146: 1037-45.
132. Suarez DL, Whetstone CA. Identification of hypervariable and conserved regions in the surface envelope gene in the bovine lentivirus. Virology 1995; 212: 728-33.
133. Suarez DL, Whetstone CA. Size variation within the second hypervariable region of the surface envelope gene of the bovine lentivirus BIV in experimentally and naturally infected cattle. J Virol 1997; 71: 2482-6.
134. Suarez DL, VanDerMaaten MJ, Wood C, Whetstone CA. Isolation and characterization of new wild-type isolates of bovine lentivirus. J Virol 1993; 67: 5051-5.
135. Golub EI, Li GG, Volsky DJ. Differences in the basal activity of the long terminal repeat determine different replicative capacities of two closely related human immunodeficiency virus type 1 isolates. J Virol 1990; 64: 3654-60.
136. Hiebenthal-Millow K, Greenough TC, Bretttler DB, et al. Alterations in HIV-1 LTR promoter activity during AIDS progression. Virology 2003; 317: 109-18.
137. Hua J, Caffrey JJ, Cullen BR. Functional consequences of natural sequence variation in the activation domain of HIV-1 Rev. Virology 1996; 222: 423-9.
138. Krebs FC, Mehrens D, Pomeroy S, Goodenow MM, Wigdahl B. Human immunodeficiency virus type 1 long terminal repeat quasispecies differ in basal transcription and nuclear factor recruitment in human glial cells and lymphocytes. J Biomed Sci 1998; 5: 31-44.
139. Martins LP, Chenciner N, Asjo B, Meyerhans A, Wain-Hobson S. Independent fluctuation of human immunodeficiency virus type 1 rev and gp41 quasispecies in vivo. J Virol 1991; 65: 4502-7.
140. Nagashunmugam T, Velpandi A, Otsuka T, Cartas M, Srinivasan A. Analysis of the viral determinants underlying replication kinetics and cellular tropism of human immunodeficiency virus. Pathobiology 1992; 60: 234-45.
141. Peloponese JM, Jr., Collette Y, Gregoire C, et al. Full peptide synthesis, purification, and characterization of six Tat variants. Differences observed between HIV-1 isolates from Africa and other continents. J Biol Chem 1999; 274: 11473-8.
142. Zhang MJ, Dayton AI. Tolerance of diverse amino acid substitutions at conserved positions in the nuclear export signal (NES) of HIV-1 Rev. Biochem Biophys Res Commun 1998; 243: 113-6.
143. Belshan M, Harris ME, Shoemaker AE, Hope TJ, Carpenter S. Biological characterization of Rev variation in equine infectious anemia virus. J Virol 1998; 72: 4421-6.
144. Belshan M, Baccam P, Oaks JL, et al. Genetic and biological variation in equine infectious anemia virus Rev correlates with variable stages of clinical disease in an experimentally infected pony. Virology 2001; 279: 185-200.
145. Benko DM, Schwartz S, Pavlakis GN, Felber BK. A novel human immunodeficiency virus type 1 protein, tev, shares sequences with tat, env, and rev proteins. J Virol 1990; 64: 2505-18.
146. Salfeld J, Gottlinger HG, Sia RA, Park RE, Sodroski JG, Haseltine WA. A tripartite HIV-1 tat-env-rev fusion protein. EMBO J 1990; 9: 965-70.
147. Cojocariu M, St-Louis MC, Archambault D. Bovine immunodeficiency virus: identification of a long terminal repeat sequence with enhanced promoter activity. Arch Virol 2009; 154: 1163-7.
148. Matukonis M, Li M, Molina RP, Paszkiet B, Kaleko M, Luo T. Development of second- and third-generation bovine immunodeficiency virus-based gene transfer systems. Hum Gene Ther 2002; 13: 1293-303.
149. Molina RP, Matukonis M, Paszkiet B, Zhang J, Kaleko M, Luo T. Mapping of the bovine immunodeficiency virus packaging signal and RRE and incorporation into a minimal gene transfer vector. Virology 2002; 304: 10-23.
150. Molina RP, Ye HQ, Brady J, et al. A synthetic Rev-independent bovine immunodeficiency virus-based packaging construct. Hum Gene Ther 2004; 15: 865-77.
151. Athanassiou Z, Dias RL, Moehle K, Dobson N, Varani G, Robinson JA. Structural mimicry of retroviral tat proteins by constrained beta-hairpin peptidomimetics: ligands with high affinity and selectivity for viral TAR RNA regulatory elements. J Am Chem Soc 2004; 126: 6906-13.
152. Athanassiou Z, Patora K, Dias RL, Moehle K, Robinson JA, Varani G. Structure-guided peptidomimetic design leads to nanomolar beta-hairpin inhibitors of the Tat-TAR interaction of bovine immunodeficiency virus. Biochemistry 2007; 46: 741-51.
153. Mills NL, Shelat AA, Guy RK. Assay Optimization and Screening of RNA-Protein Interactions by AlphaScreen. J Biomol Screen 2007; 12: 946-55.
154. Runyon ST, Puglisi JD. Design of a cyclic peptide that targets a viral RNA. J Am Chem Soc 2003; 125: 15704-5.